目的:本研究旨在探讨CD276与肾透明细胞癌(ccRCC)的关系,并评估CD276在ccRCC中的诊断价值。
方法:使用TCGA和GEO数据库获得的数据对ccRCC和癌旁组织中CD276的表达水平进行比较和回顾性分析。对其临床资料进行前瞻性分析。免疫组织化学和RT-PCR分析用于在mRNA和蛋白质水平上分析CD276的表达。这些分析比较了从70例ccRCC患者获得的ccRCC组织和癌旁组织之间的表达。接下来,采用ELISA方法对70例ccRCC患者和72例健康人的外周血标本进行分析,促进ccRCC患者与正常对照的分化。最后,我们利用Kaplan-Meier方法生成ROC曲线,以评估CD276对ccRCC的诊断价值.
结果:对TCGA和GEO数据的分析表明,ccRCC组织中CD276的mRNA表达高于癌旁组织(P<0.05)。IHC和RT-PCR的临床验证证实,ccRCC组织中CD276的表达高于癌旁组织,在mRNA和蛋白质水平(P<0.05)。ELISA显示ccRCC患者中CD276的表达高于正常人,病理分级较高的患者外周血CD276的表达高于病理分级较低的患者(P<0.05)。从上述三个数据集绘制的ROC曲线表明,CD276对ccRCC具有较高的诊断价值(AUC分别为.894,.795,.938)。
结论:ccRCC组织中CD276的表达较高,且与病理分级呈正相关。因此,CD276可作为ccRCC预测的分子生物标志物。
OBJECTIVE: This study aimed to explore the relationship between CD276 and clear cell renal carcinoma (ccRCC) and assess the diagnostic value of CD276 in ccRCC.
METHODS: Expression levels of CD276 in ccRCC and para-cancer tissues were compared and analyzed retrospectively using data obtained from TCGA and GEO databases. The clinical data was analyzed prospectively. Immunohistochemistry and RT-PCR analyses were used to analyze the expression of CD276 at the mRNA and protein levels. These analyses compared the expression between ccRCC tissues and para-cancer tissues obtained from 70 patients with ccRCC. Next, ELISA was used to analyze peripheral blood samples from 70 patients with ccRCC and 72 healthy individuals, facilitating the differentiation of ccRCC patients from normal controls. Finally, we utilized the Kaplan-Meier method to generate ROC curves for assessing the diagnostic value of CD276 for ccRCC.
RESULTS: Analysis of TCGA and GEO data revealed that the mRNA expression of CD276 was higher in ccRCC tissues than in para-cancer tissues (P < .05). Clinical validation using IHC and RT-PCR confirmed that the expression of CD276 was higher in ccRCC tissues than in para-cancer tissues, both at the mRNA and protein levels (P < .05). ELISA demonstrated that the expression of CD276 was higher in ccRCC patients than in normal individuals, and patients with a higher pathological grade showed higher expression of CD276 in the peripheral blood than those with a lower pathological grade (P < .05). ROC curves drawn from the above three datasets demonstrated that CD276 had a high diagnostic value for ccRCC (AUC = .894, .795, .938, respectively).
CONCLUSIONS: The expression of CD276 was higher in ccRCC tissues and positively associated with the pathological grade. Therefore, CD276 may serve as a molecular biomarker for ccRCC prediction.